Previous 10 | Next 10 |
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awa...
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2021 financial results after the U.S. financial mar...
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of two abstracts at the American Society of Clinical Oncology (ASCO)...
The first week of AACR 2021 (American Association of Cancer Research Annual Meeting) has concluded with Affimed (AFMD) emerging as a clear winner while iTeos Therapeutics (ITOS) disappointed with an early-stage study for its lead asset.The presentations from Eli Lilly (LLY), Oncternal Therape...
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company wi...
Oncternal Therapeutics (ONCT) announces the presentation of three posters at the AACR Meeting 2021. Poster Title: A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced/Unresectable or Metastatic Her2 Negative Breast CancerOf 15 intent-to-treat patients, eight patients (...
iRhythm Technologies (IRTC) -30% after Novitas publishes updated reimbursement rates.Qualigen Therapeutics (QLGN) -18% after it pulls marketing application for COVID-19 test.Gulf Resources (GURE) -11% on correcting and replacing - Q4 & FY2020 financial result...
Updated interim results of a Phase 1b trial of cirmtuzumab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer showed 57% of evaluable patients (8 of 14) had a partial response and 29% (4 of 14) had stable disease. In a preclinical study...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...
Provention Bio (PRVB) -38% after gives update on teplizumab BLA, FDA feedback.Virpax Pharmaceuticals (VRPX) -18%.Chemomab Therapeutics (CMMB) -17%.Iterum Therapeutics (ITRM) -15% after receiving notice from FDA on its NDA drug application for sulopenem etzadroxil/probenecid for...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...